.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
As always, if you know of layoffs occurring at a biotech, please reach out to th...
That includes treating more than 200,000 patients with the irregular heartbeat k...
Glucotrack has cleared the first human clinical study of its long-term continuou...
X4 Pharmaceuticals is laying off 30% of its staff and halting preclinical R&D as...
AstraZeneca has ended development of its oral factor D inhibitor vemircopan, tri...
LinusBio aims to help physicians rule out the likelihood of autism developing in...
The “New BD,” as the company describes it, will continue on as a pure-play medte...
Kura Oncology and Kyowa Kirin claim to have scored a phase 2 win for their oral ...
Eli Lilly has invested heavily into obesity, dominating the landscape—alongside ...
Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joi...
Eye-disease-focused Acelyrin will be absorbed into immune-mediated disease speci...
After sharing plans to shutter last summer, Asarina Pharma has managed to sell o...
Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plan...
The procedure was performed January 25 by surgeons at the Mass General Transplan...
The DNA sequencing giant said it will continue to do business in China as long a...
Researchers have used artificial intelligence to identify 25 new protein compoun...
After re-adding Blenrep to its portfolio, GSK now expects sales to reach more th...
Amar Urhekar has reset Avalere Health’s mission. Weeks after naming Urhekar as C...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
After recent launches of biosimilar versions of Eylea and Stelara, Amgen project...
As Moderna maps out a more cautious future amid lower-than-expected sales of its...
The CDC Foundation has added muscle to its “Live to the Beat” campaign, enlistin...
AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma...
The company is in talks with individual regulatory authorities after its decisio...